Company Analysis: Shuttle Pharmaceuticals Holdings, Inc. (SHPH)

Introduction

Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing therapies aimed at improving cancer treatment outcomes. The company is headquartered in Gaithersburg, Maryland, and was founded in December 2012 by a team that includes Dr. Anatoly Dritschilo, who currently serves as the Chairman and Chief Scientific Officer.

Corporate Structure

Shuttle Pharmaceuticals operates with a team of approximately 9 individuals. The company utilizes proprietary technology to create therapies designed to enhance the effectiveness of existing cancer treatments, including surgery, radiation therapy, chemotherapy, and immunotherapy.

Recent Developments

• Stock Performance: As of May 12, 2025, SHPH's stock price is $0.3193, reflecting a price increase of 37.33% with a trading volume of 395,351 shares on the NASDAQ exchange.
• Clinical Trials: On May 8, 2025, Shuttle Pharmaceuticals announced that it has achieved nearly 50% enrollment in its Phase 2 clinical trial for Ropidoxuridine, which is being investigated for the treatment of glioblastoma. The trial aims to determine the optimal dosage and assess the drug's efficacy in combination with radiation therapy.
• Funding: On March 13, 2025, the company closed a $5.75 million underwritten public offering. The proceeds from this offering are intended to support the Phase 2 clinical trial, marketing efforts, and general corporate purposes.

Financial Analysis

• Market Capitalization: As of May 12, 2025, Shuttle Pharmaceuticals has a market cap of approximately $1.45 million.
• Financial Metrics:
  • Price-to-Earnings Ratio (P/E): Not applicable as the company is not currently profitable.
  • Net Income: The company reported a net income loss of $10.47 million.
  • Total Cash: The company holds approximately $4.51 million in cash.
  • Total Debt/Equity Ratio: 33.61%, indicating a moderate level of debt relative to equity.

Market Position and Industry Context

Shuttle Pharmaceuticals operates within the healthcare sector, specifically in the drug manufacturing industry focused on specialty and generic drugs. The company aims to address unmet needs in cancer treatment through its development of radiation sensitizers. The market for radiation therapy is significant, with an estimated 800,000 patients treated annually in the U.S. for various cancers.

TL;DR

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is currently trading at $0.3193, up 37.33%, with a market cap of $1.45 million. The company is advancing its Phase 2 clinical trial for Ropidoxuridine, nearing 50% enrollment as of May 8, 2025. On March 13, 2025, it raised $5.75 million to support its clinical and operational activities. The company aims to enhance cancer treatment outcomes through innovative therapies.